Skip to main content

Table 1 Clinical trials evaluating combination of epigenetic inhibitors and immunotherapies

From: Leveraging epigenetics to enhance the efficacy of immunotherapy

Epigenetic therapy Immunotherapy Cancer type Phase, Trial ID
Histone deacetylase inhibitors (target)    
CXD101 (Pan HDAC) Nivolumab (PD-1) Colorectal cancer I/II, NCT03993626
Domatinostat (HDAC1,2,3) Avelumab (PD-L1) GI cancer II, NCT03812796
Entinostat (HDAC1,2,3) Pembrolizumab (PD-1) Bladder cancer II, NCT03978624
Melanoma II, NCT03765229
MDS I, NCT02936752
Metastatic uveal melanoma II, NCT02697630
  Atezolizumab (PD-L1) Breast cancer I/II, NCT03280563
  Nivolumab (PD-1) Cholangiocarcinoma, pancreatic adenocarcinoma II, NCT03250273
  Aldesleukin (IL-2) Renal cell carcinoma I/II, NCT01038778
  Nivolumab (PD-1), Ipilimumab (CTLA-4) Breast cancer I, NCT02453620
Mocetinostat (Pan HDAC) Durvalumab (PD-L1) NSCLC I/II, NCT02805660
Tinostamustine (Pan HDAC) Nivolumab (PD-1) Melanoma I, NCT03903458
Vorinostat (Pan HDAC) Pembrolizumab (PD-1) Lymphomas I, NCT03150329
Renal cell carcinoma I, NCT02619253
NSCLC I/II, NCT02638090
Head and neck I/II, NCT02538510
DNA methyltransferase inhibitors    
Azacytidine Avelumab (PD-L1) DLBCL III, NCT02951156
  Alemtuzumab (CD52) Myeloid malignancies II, NCT02497404
  Pembrolizumab (PD-1) AML II, NCT02845297
AML II, NCT03769532
Pancreatic cancer II, NCT03264404
MDS II, NCT03094637
Oral azacytidine (CC-486) Pembrolizumab (PD-1) Ovarian cancer II, NCT02900560
NSCLC II, NCT02546986
Melanoma II, NCT02816021
Decitabine Pembrolizumab (PD-1) T cell lymphomas II, NCT03240211
Lymphomas I, NCT03445858
AML I, NCT03969446
Breast cancer II, NCT02957968
  Anti-PD-1 antibody Solid tumors I/II, NCT02961101
  Dendritic cell vaccine (NY-ESO-1, MAGE-A1 MAGE-A3) Pediatric brain tumors I/II, NCT02332889
Guadecitabine Atezolizumab (PD-L1) Urothelial carcinoma II, NCT03179943
  Durvalumab (PD-L1) Liver, pancreatic, bile duct, gallbladder I, NCT03257761
  GVAX (Cell vaccine) Colon cancer I, NCT01966289
  Ipilimumab (CTLA-4) Melanoma I, NCT02608437
  Pembrolizumab (PD-1) Ovarian II, NCT02901899
Prostate, NSCLC I, NCT02998567
Histone modifications (target)    
Tazemetostat (EZH2) Pembrolizumab (PD-1) Bladder cancer I/II, NCT03854474
CPI-1205 (EZH2) Ipilimumab (CTLA-4) Solid tumors I/II, NCT03525795
BMS-986158 (BRD2/3/4, BRDT) Nivolumab (PD-1) Advanced tumors I/II, NCT02419417
Multiple combinations    
Azacytidine, entinostat Nivolumab NSCLC II, NCT01928576
Azacytidine, venetoclax (Bcl-2) Pembrolizumab AML II, NCT04284787
Azacytidine, epacadostat (IDO-1) Pembrolizumab Metastatic solid tumors I/II, NCT02959437
Mocetinostat, guadecitabine Pembrolizumab Lung cancer I, NCT03220477
Vorinostat, temozolomide Pembrolizumab Glioblastoma I, NCT03426891
Vorinostat, tamoxifen Pembrolizumab Breast cancer II, NCT04190056
II, NCT02395627
Multiple agents Multiple agents Breast, prostrate, pancreas, AML I, NCT03878524
Azacytidine, romidepsin (Pan HDAC) Pembrolizumab Colorectal cancer I, NCT02512172
Azacytidine Tremelimumab (CTLA-4)
Durvalumab (PD-L1)
Head and neck cancer I/II, NCT03019003
Decitabine, tetrahydrouridine Pembrolizumab NSCLC I/II, NCT03233724